Insights

The Insights page consists of Insight Articles, Commentaries, C-level Q&As, Discussion Group Reports, and Survey Reports.

Commentary
At the 2021 Immuno Week: Online event, we sat down with an advisory board comprised of key figures from some of the top biotech companies and research institutions to discuss the acute need for improved combination therapies and predictive biomarkers in immuno-oncology.
By Tia Byer |
22 September 2021
Biomarkers in Immuno-Oncology
Commentary
Patient-specific medicine in Immunotherapy and Immuno-oncology is fast becoming a globally recognised form of cancer treatment. But how easy is it to apply AI and ML to tailor a treatment for each individual patient? Director of Genomic Immuno-Oncology at Evaxion Biotech, Jens Kringelum, investigates how best to integrate data generation and ML to decode the immune system.
By Tia Byer |
16 September 2021
Biomarkers in Immuno-Oncology
Insight Article
Katharina Billian-Frey, Senior Scientist Drug Discovery/Protein Engineering, Apogenix AG
20 May 2019
Therapeutic Modalities
Insight Article
Graham Pockley, Chief Executive Officer, multimmune GmbH, Director, Nottingham Trent University
11 October 2018
Therapeutic Modalities
Insight Article
Troels Jordansen, Chief Executive Officer, Glycostem Therapeutics
24 May 2018
Therapeutic Modalities
Advertisement

We produce cutting edge congresses and summits for the Life Sciences Industry, bringing together industry leaders and solution providers at a senior level, creating the opportunity to partner, network and knowledge share.

Contact Us:

Copyright Oxford Global Marketing Limited. All rights reserved.

Stay up to date

Sign up for our monthly Editorial Newsletter to keep up with all things Immuno

Submit your details to receive the monthly newsletter & to be kept up to date about relevant events, monthly discussion groups and portal membership offers. You may opt-out at any time. Please check our Privacy Policy to see how Oxford Global protects and manages your data.